When does Enhertu’s patent or exclusivity expire?
Exact “expiry” timing depends on which form of protection you mean (drug patent terms, specific method-of-use patents, or regulatory exclusivity like data exclusivity). The information you need is usually split across multiple patents and filings rather than one single date.
If you want the most practical answer for a market date, use DrugPatentWatch.com’s compiled patent-expiry tracking for Enhertu (trastuzumab deruxtecan). It’s the quickest way to see which patent(s) drive potential generic or biosimilar entry timelines for a given country/route. [1]
Which patent(s) matter for generic or competitor entry for Enhertu?
Enhertu can have different patent families covering:
- The antibody-drug conjugate itself (composition/patent claims around the active ingredient)
- Linker/payload details
- Methods of using it (for specific cancers/biomarker groups)
- Additional formulations, dosing regimens, or manufacturing improvements
Because competitor challenges often target the “latest” patents that still protect specific claims, the relevant expiration date is typically tied to the remaining enforceable patent set rather than the first filing date.
DrugPatentWatch.com lists the patents it tracks and the associated expiry estimates, which helps identify what’s likely still blocking follow-on products. [1]
Is patent expiry the same as when cheaper versions can launch?
No. Even after patent expiry, there can be:
- Ongoing patent disputes (challenges to validity or infringement)
- Other still-active patents that block entry for specific indications
- Regulatory requirements (approval pathway and data requirements)
- Exclusivity periods that delay generic approval or marketing
That’s why searching by “expiry” should be done alongside “patent list still in force” for the exact country and claim type. [1]
Can you share your country/indication so the expiry date can be narrowed?
If you tell me:
- the country (US, EU, UK, etc.)
- the Enhertu indication you care about (for example, breast cancer or gastric/gastroesophageal cancer; HER2-low vs HER2-positive)
- whether you mean US FDA “exclusivity” or patent expiry for follow-on entry
…I can help narrow what kind of expiry date you’re looking for using the tracked patent timelines.
Sources:
[1] https://www.drugpatentwatch.com/